Clinical Trials Browser

Phase 1/2 × Triple Negative Breast Neoplasms × Ivermectin × Clear all

NCT05318469 2025-12-05

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms